New US diabetes drug pipeline report as cases escalate
A new report has been unveiled at an event in Raleigh, North Carolina, about medicines in the research pipeline for diabetes by the Pharmaceutical Research and Manufacturers of America (PhRMA). The study shows that US pharmaceutical and biotechnology firms are testing a record 183 new diabetes medicines. The products listed in the report are in clinical trials or await approval by the Food and Drug Administration.
"We released this report in North Carolina because of the alarming rise in the number of new cases of diabetes in the state. Unfortunately, these rising numbers reflect what is occurring nationwide," said the PhRMA's senior vice president Ken Johnson, who presented the report's findings at the SAS Institute located in the Research Triangle Park Corridor. SAS has a successful diabetes management program for its employees.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze